{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T06:33:43Z","timestamp":1791614023205,"version":"4.3.4"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T00:00:00Z","timestamp":1745366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T00:00:00Z","timestamp":1745366400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1038\/s41409-025-02596-0","type":"journal-article","created":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T07:18:20Z","timestamp":1745392700000},"page":"1027-1035","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Allogeneic stem cell transplantation in de novo core-binding factor acute myeloid leukemia in active disease: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation"],"prefix":"10.1038","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-5168-7243","authenticated-orcid":false,"given":"Sara","family":"Tarantino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myriam","family":"Labopin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6565-3393","authenticated-orcid":false,"given":"Robert","family":"Zeiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9331-5145","authenticated-orcid":false,"given":"Matthias","family":"Stelljes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Schroeder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5103-9966","authenticated-orcid":false,"given":"Nicolaus","family":"Kr\u00f6ger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6052-2618","authenticated-orcid":false,"given":"Wolfgang","family":"Bethge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7092-3351","authenticated-orcid":false,"given":"Jakob","family":"Passweg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5916-3029","authenticated-orcid":false,"given":"Martin","family":"Bornh\u00e4user","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1821-1976","authenticated-orcid":false,"given":"Johanna","family":"Tischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Eder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4471-418X","authenticated-orcid":false,"given":"Eolia","family":"Brissot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8056-648X","authenticated-orcid":false,"given":"Jordi","family":"Esteve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnon","family":"Nagler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7264-808X","authenticated-orcid":false,"given":"Mohamad","family":"Mohty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Ciceri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,23]]},"reference":[{"key":"2596_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2023.101117","volume":"62","author":"C Darwish","year":"2023","unstructured":"Darwish C, Farina K, Tremblay D. The core concepts of core binding factor acute myeloid leukemia: Current considerations for prognosis and treatment. Blood Rev. 2023;62:101117. https:\/\/doi.org\/10.1016\/j.blre.2023.101117.","journal-title":"Blood Rev"},{"key":"2596_CR2","doi-asserted-by":"publisher","unstructured":"Ye Y, Labopin M, G\u00e9rard S, Yakoub-Agha I, Blau IW, Aljurf M, et al. Lower relapse incidence with haploidentical versus matched sibling or unrelated donor hematopoietic cell transplantation for core-binding factor AML patients in CR2: A study from the Global Committee and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Am J Hematol. 2024. https:\/\/doi.org\/10.1002\/ajh.27342.","DOI":"10.1002\/ajh.27342"},{"key":"2596_CR3","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.3324\/haematol.2019.222810","volume":"105","author":"K Halaburda","year":"2020","unstructured":"Halaburda K, Labopin M, Mailhol A, Soci\u00e9 G, Craddock C, Aljurf M, et al. Allogeneic stem cell transplantation in second complete remission for core binding factor acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Haematologica. 2020;105:1723\u201330. https:\/\/doi.org\/10.3324\/haematol.2019.222810.","journal-title":"Haematologica"},{"key":"2596_CR4","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1002\/ajh.23821","volume":"89","author":"M Solh","year":"2014","unstructured":"Solh M, Yohe S, Weidorf D, Ustun C. Core-binding factor acute myeloid leukemia: heterogeneity, monitoring and therapy. Am J Hematol. 2014;89:1121\u201331.","journal-title":"Am J Hematol"},{"key":"2596_CR5","doi-asserted-by":"crossref","unstructured":"Sinha C, Cunningham LC, Liu PP. Core binding factor acute myeloid leukemia: new prognostic categories and therapeutic opportunities. Semin Hematol. 2015;52:215\u201322.","DOI":"10.1053\/j.seminhematol.2015.04.002"},{"key":"2596_CR6","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1182\/bloodadvances.2019000168","volume":"4","author":"S Al-Harbi","year":"2020","unstructured":"Al-Harbi S, Aljurf M, Mohty M, Almohareb F, Ahmed SOA. An update on the molecular pathogenesis and potential therapeutic targeting of AML with t(8;21)(q22;q22.1);RUNX1-RUNX1T1. Blood Adv. 2020;4:229\u201338.","journal-title":"Blood Adv"},{"key":"2596_CR7","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H D\u00f6hner","year":"2017","unstructured":"D\u00f6hner H, Estey E, Grimwade D. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424\u201347. https:\/\/doi.org\/10.1182\/blood-2016-08-733196.","journal-title":"Blood"},{"key":"2596_CR8","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1111\/j.1365-2141.2006.06276.x","volume":"135","author":"FR Appelbaum","year":"2006","unstructured":"Appelbaum FR, Kopecky KJ, Tallman MS. The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations. Br J Haeamtol. 2006;135:165\u201373.","journal-title":"Br J Haeamtol"},{"key":"2596_CR9","doi-asserted-by":"publisher","first-page":"524","DOI":"10.3324\/haematol.2017.187450","volume":"104","author":"E Brissot","year":"2019","unstructured":"Brissot E, Labopin M, Ehninger G, Stelljes M, Brecht A, Ganser A, et al. Haploidentical versus unrelated allogeneic stem cell transplantation for relapsed\/refractory acute myeloid leukemia: a report on 1578 patients from the Acute Leukemia Working Party of the EBMT. Haematologica. 2019;104:524\u201332. https:\/\/doi.org\/10.3324\/haematol.2017.187450.","journal-title":"Haematologica"},{"key":"2596_CR10","doi-asserted-by":"publisher","unstructured":"Maffini E, Labopin M, Kr\u00f6ger N, Finke J, Stelljes M, Schroeder T et al. Allogeneic hematopoietic cell transplantation for older patients with AML with active disease. A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant. 2024. https:\/\/doi.org\/10.1038\/s41409-024-02275-6.","DOI":"10.1038\/s41409-024-02275-6"},{"key":"2596_CR11","doi-asserted-by":"publisher","first-page":"3730","DOI":"10.1200\/JCO.2010.28.8852","volume":"28","author":"M Duval","year":"2010","unstructured":"Duval M, Klein JP, He W. Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure. J Clin Oncol. 2010;28:3730\u20138. https:\/\/doi.org\/10.1200\/JCO.2010.28.8852.","journal-title":"J Clin Oncol"},{"key":"2596_CR12","doi-asserted-by":"publisher","first-page":"e384","DOI":"10.1016\/S2352-3026(15)00146-5","volume":"2","author":"A Nagler","year":"2015","unstructured":"Nagler A, Savani BN, Labopin M. Outcomes after use of two standard ablative regimens in patients with refractory acute myeloid leukaemia: a retrospective, multicentre, registry analysis. Lancet Haematol. 2015;2:e384\u2013392.","journal-title":"Lancet Haematol"},{"key":"2596_CR13","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1038\/bmt.2017.8","volume":"52","author":"B Gyurkocza","year":"2017","unstructured":"Gyurkocza B, Lazarus HM, Giralt S. Allogeneic hematopoietic cell transplantation in patients with AML not achieving remission: potentially curative therapy. Bone Marrow Transplant. 2017;52:1083\u201390.","journal-title":"Bone Marrow Transplant"},{"key":"2596_CR14","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1002\/ajh.23655","volume":"89","author":"E Jabbour","year":"2014","unstructured":"Jabbour E, Daver N, Champlin R, Mathisen M, Oran B, Ciurea S, et al. Allogeneic stem cell transplantation as initial salvage for patients with acute myeloid leukemia refractory to high-dose cytarabine-based induction chemotherapy. Am J Hematol. 2014;89:395\u20138.","journal-title":"Am J Hematol"},{"key":"2596_CR15","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s13045-017-0498-8","volume":"10","author":"E Brissot","year":"2017","unstructured":"Brissot E, Labopin M, Stelljes M. Comparison of matched sibling donors versus unrelated donors in allogeneic stem cell transplantation for primary refractory acute myeloid leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT. J Hematol Oncol. 2017;10:130.","journal-title":"J Hematol Oncol"},{"key":"2596_CR16","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1038\/leu.2011.13","volume":"25","author":"C Craddock","year":"2011","unstructured":"Craddock C, Labopin M, Pillai S. Factors predicting outcome after unrelated donor stem cell transplantation in primary refractory acute myeloid leukaemia. Leukemia. 2011;25:808\u201313. https:\/\/doi.org\/10.1038\/leu.2011.13.","journal-title":"Leukemia"},{"key":"2596_CR17","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","volume":"15","author":"A Bacigalupo","year":"2009","unstructured":"Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant. 2009;15:1628\u201333.","journal-title":"Biol Blood Marrow Transplant"},{"key":"2596_CR18","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.bbmt.2015.09.001","volume":"22","author":"AC Harris","year":"2016","unstructured":"Harris AC, Young R, Devine S, Hogan WJ, Ayuk F, Bunworasate U, et al. International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the Mount Sinai acute GVHD international consortium. Biol Blood Marrow Transplant. 2016;22:4\u201310.","journal-title":"Biol Blood Marrow Transplant"},{"key":"2596_CR19","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","volume":"21","author":"MH Jagasia","year":"2015","unstructured":"Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 diagnosis and staging working group report. Biol Blood Marrow Transplant. 2015;21:389\u2013401.e381.","journal-title":"Biol Blood Marrow Transplant"},{"key":"2596_CR20","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1038\/bmt.2015.305","volume":"51","author":"A Ruggeri","year":"2016","unstructured":"Ruggeri A, Labopin M, Ciceri F, Mohty M, Nagler A. Definition of GvHD-free, relapse-free survival for registry-based studies: an ALWP-EBMT analysis on patients with AML in remission. Bone Marrow Transplant. 2016;51:610\u20131.","journal-title":"Bone Marrow Transplant"},{"key":"2596_CR21","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345\u201377. https:\/\/doi.org\/10.1182\/blood.2022016867.","journal-title":"Blood"},{"key":"2596_CR22","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/j.leukres.2014.04.001","volume":"38","author":"A Brunner","year":"2014","unstructured":"Brunner A, Blonquist T, Sadrzadeh H, Perry A, Attar E, Amrein P, et al. Population-based disparities in survival among patients with Core-binding factor acute myeloid leukemia: a SEER database analysis. Leuk Res. 2014;38:773\u201380.","journal-title":"Leuk Res"},{"key":"2596_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32103-8","volume":"13","author":"Y Tazi","year":"2022","unstructured":"Tazi Y, Arango-Ossa JE, Zhou Y, Bernard E, Thomas I, Gilkes A, et al. Unified classification and risk-stratification in acute myeloid leukemia. Nat Commun. 2022;13:4622.","journal-title":"Nat Commun"},{"key":"2596_CR24","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.1182\/blood-2014-03-563403","volume":"124","author":"Y Wang","year":"2014","unstructured":"Wang Y, Wu DP, Liu QF, Qin YZ, Wang JB, Xu LP, et al. In adults with t(8;21)AML, posttransplant RUNX1\/RUNX1T1-based MRD monitoring, rather than c-KIT mutations, allows further risk stratification. Blood. 2014;124:1880\u20136.","journal-title":"Blood"},{"key":"2596_CR25","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1182\/blood-2014-01-549212","volume":"124","author":"MA Hospital","year":"2014","unstructured":"Hospital MA, Prebet T, Bertoli S, Thomas X, Tavernier E, Braun T, et al. Core binding factor acute myeloid leukemia in first relapse: a retrospective study from the French AML intergroup. Blood. 2014;124:1312\u20131319.17.","journal-title":"Blood"},{"key":"2596_CR26","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1200\/JCO.2011.40.5977","volume":"31","author":"AK Burnett","year":"2013","unstructured":"Burnett AK, Goldstone A, Hills RK, Milligan D, Prentice A, Yin J, et al. Curability of patients with acute myeloid leukemia who did not undergo transplanta tion in first remission. J Clin Oncol. 2013;31:1293\u2013301.","journal-title":"J Clin Oncol"},{"key":"2596_CR27","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1182\/blood-2014-10-551911","volume":"126","author":"F Thol","year":"2015","unstructured":"Thol F, Schlenk RF, Heuser M, Ganser A. How I treat refractory and early relapsed acute myeloid leukemia. Blood. 2015;126:319\u201327.","journal-title":"Blood"},{"key":"2596_CR28","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/s41375-023-02119-0","volume":"38","author":"M Yanada","year":"2024","unstructured":"Yanada M, Yamasaki S, Kondo T, Kawata T, Harada K, Uchida N, et al. Allogeneic hematopoietic cell transplantation for patients with acute myeloid leukemia not in remission. Leukemia. 2024;38:513\u201320.","journal-title":"Leukemia"},{"key":"2596_CR29","doi-asserted-by":"publisher","first-page":"3463","DOI":"10.1182\/blood-2005-09-3640","volume":"107","author":"R Cairoli","year":"2006","unstructured":"Cairoli R, Beghini A, Grillo G, Nadali G, Elice F, Ripamonti CB, et al. Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study. Blood. 2006;107:3463\u20138.","journal-title":"Blood"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02596-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02596-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02596-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T03:06:02Z","timestamp":1751857562000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02596-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,23]]},"references-count":29,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["2596"],"URL":"https:\/\/doi.org\/10.1038\/s41409-025-02596-0","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,23]]},"assertion":[{"value":"27 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was approved by the Institutional Review Board of the ALWP of the EBMT and complied with country-specific regulatory requirements. All methods involving human participants were carried out in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki Declaration and its later amendments. Patients provide informed consent authorizing the use of their personal information for research purposes.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}